Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

N/A

2(66.7%)

Phase 3

1(33.3%)

3Total

N/A(2)

Phase 3(1)

Loading network data...

Showing 5 of 5 trials

Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

Role: collaborator

Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

Role: collaborator

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Role: collaborator

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Role: collaborator

A Randomized Controlled Trial:Treatments on Infundibular Ventricular Septal Defect

Role: collaborator

All 5 trials loaded